EHMT2 and cancer: Anti-cancer drugs (HMT inhibitors) have also been developed that target the HMTs EZH2, DOT1-like histone lysine methyltransferase (DOT1L), euchromatic histone lysine methyltransferase 2 (G9A), the histone-lysine N-methyltransferase SUV39H1 and protein arginine methyltransferases (PRMT1/3/45/6/8).